Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Orciprenaline→

Orciprenaline Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
586-06-1
Molecular formula
C11H17NO3
Molecular weight
211.26 g/mol
Drug class
Non-selective beta-adrenergic receptor agonistbronchodilator (metaproterenol)
Mechanism of action
Stimulates beta-2 adrenergic receptors in bronchial smooth muscle, increasing intracellular cyclic AMP and causing bronchodilation. It also has beta-1 activity, particularly at higher systemic exposure.
Indications / reported uses
  • Relief of bronchospasm in asthma and reversible obstructive airway disease in countries where orciprenaline products remain authorised; clinical use and availability are jurisdiction-specific

Sources: NLM MeSH — Metaproterenol/orciprenaline · PubMed — Orciprenaline beta-agonist pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Orciprenaline Environmental Risk Assessment (ERA) (the Orciprenaline ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.